1-3 of 3
Michele L Nassin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease Aged 6 to <12 Years: 2-Year Data from the Phase 2 Solace-Kids Study

Matthew M. Heeney, David C Rees, Slimane Allali, Isaac Odame, Rodolfo D Cançado, Adlette Inati, Elena Cela, Deborah Keefe, Evgeniya Reshetnyak, Velusamy Shanmuganathan Muthusamy, Lidiya Bebrevska, Michele L Nassin, Julie Kanter
Journal: Blood
Blood (2024) 144 (Supplement 1): 180.
https://doi.org/10.1182/blood-2024-207207
Published: 2024
Journal Articles

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Guvenc, Deborah Keefe, Kai Grosch, Michele L Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Dei Adomakoh
Journal: Blood
Blood (2023) 142 (Supplement 1): 272.
https://doi.org/10.1182/blood-2023-185429
Published: 2023
Journal Articles

Immune System Profiling Following Autologous Stem Cell Transplant for High-Risk Neuroblastoma Predicts Disease-Free Survival

Michele L Nassin, MD, Elitsa V Nicolaou, MD, Hillary M Hecktman, CPNP-AC, Caitlin W Cohen, CPNP-AC, Susan L Cohn, MD, John M Cunningham, MD, James L LaBelle, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2251.
https://doi.org/10.1182/blood.V128.22.2251.2251
Published: 2016